var data={"title":"Nisoldipine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nisoldipine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6658?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nisoldipine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nisoldipine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201814\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sular</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201845\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Calcium Channel Blocker;</li>\n      <li>\n        Calcium Channel Blocker, Dihydropyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201818\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sular (Geomatrix delivery system):</b> Oral: Initial: 17 mg once daily, then increase by 8.5 mg/week (or longer intervals) to attain adequate control of blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Usual dose range:</i> 17-34 mg once daily; doses &gt;34 mg once daily are not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nisoldipine extended-release tablet (original formulation):</b> Initial: 20 mg once daily, then increase by 10 mg/week (or longer intervals) to attain adequate control of blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Usual dose range:</i> 20-40 mg once daily; doses &gt;60 mg once daily are not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Conversion from nisoldipine extended-release (original formulation) to Sular Geomatrix delivery system: </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Nisoldipine Extended Release Dosing Equivalency</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Original Extended Release Formulation</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Sular Extended Release (Geomatrix delivery system)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.5 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">17 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25.5 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34 mg</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201819\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sular (Geomatrix delivery system): Initial dose: 8.5 mg once daily; increase by 8.5 mg/week (or longer intervals) to attain adequate blood pressure control</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine extended-release (original formulation): Initial dose: 10 mg once daily; increase by 10 mg/week (or longer intervals) to attain adequate blood pressure control.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Conversion from nisoldipine extended-release (original formulation) to Sular Geomatrix delivery system: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210470\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Mild to moderate impairment: No dosage adjustment necessary . </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Severe impairment: No dosage adjustment provided in  manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201820\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sular (Geomatrix delivery system): An initial dose exceeding 8.5 mg once daily is not recommended for patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Nisoldipine extended-release (original formulation): An initial dose exceeding 10 mg once daily is not recommended for patients with hepatic impairment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201793\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sular: 8.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sular: 17 mg [contains tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sular: 34 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8.5 mg, 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201780\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201797\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer at the same time each day to ensure minimal fluctuation of serum levels. Avoid high-fat diet. Administer on an empty stomach (1 hour before or 2 hours after a meal). Swallow whole; do not crush, break, split, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201796\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Management of hypertension, alone or in combination with other antihypertensive agents</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC 8 [James, 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;60 years with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &lt;60 years with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with diabetes with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD) with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic kidney disease (CKD) and hypertension: In patients with chronic kidney disease (CKD), regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diabetes and hypertension: The American Diabetes Association (ADA) guidelines suggest that for patients with hypertension and diabetes <i>without</i> albuminuria, any of the 4 classes of blood pressure medications (eg, ACE inhibitors, angiotensin receptor blockers, thiazide-like diuretics, dihydropyridine calcium channel blockers) may be used and have shown beneficial cardiovascular outcomes (ADA 2017a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201852\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nisoldipine may be confused with NIFEdipine, niMODipine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201787\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (7% to 29%; dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasodilatation (4%), palpitations (3%), exacerbation of angina pectoris (2%), chest pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (5%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, abnormal hepatic function tests, abnormal T waves on ECG (flattening, inversion, non-specific changes), alopecia, amblyopia, amnesia, anemia, anorexia, anxiety, arthralgia, arthritis, asthma, ataxia, atrial fibrillation, blepharitis, bruise, cardiac failure (decompensated), cellulitis, cerebral ischemia, cerebrovascular accident, colitis, conjunctivitis, decreased libido, depression, dermal ulcer, diabetes mellitus, diaphoresis, diarrhea, drowsiness, dysgeusia, dyspepsia, dysphagia, dyspnea, dysuria, ejection murmur (systolic), epistaxis, exfoliative dermatitis, facial edema, fever, first degree atrioventricular block, flu-like symptoms, gastritis, gastrointestinal hemorrhage, gingival hyperplasia, glaucoma, glossitis, gout, gynecomastia, hematuria, hepatomegaly, herpes simplex infection, herpes zoster, hypersensitivity reaction (eg, angioedema, chest tightness, hypotension, shortness of breath, skin rash, tachycardia), hypertension, hypertonia, hypoesthesia, hypokalemia, hypotension, increased appetite, increased blood urea nitrogen, increased creatine phosphokinase, increased nonprotein nitrogen, increased serum creatinine, insomnia, jugular vein distention, keratoconjunctivitis, leukopenia, maculopapular rash, malaise, melena, migraine, myalgia, myasthenia, myocardial infarction, myositis, nocturia, oral mucosa ulcer, orthostatic hypotension, paresthesia, petechia, pleural effusion, pruritus, pustular rash, rales, retinal detachment, skin discoloration, skin photosensitivity, supraventricular tachycardia, syncope, tenosynovitis, thyroiditis, tremor, urinary frequency, urticaria, vaginal hemorrhage, venous insufficiency, ventricular premature contractions, vertigo, vision loss (temporary, unilateral), vitreous opacity, weight changes (gain/loss), wheezing (end inspiratory wheeze), xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201800\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nisoldipine, any component of the formulation, or other dihydropyridine calcium channel blockers</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201784\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Monitor closely during initial dosing and with dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): The ACCF/AHA heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (Yancy, 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; lower starting dose required. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some dosage forms contain tartrazine, which may cause allergic reactions in certain individuals (eg, aspirin hypersensitivity). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients &gt;65 years of age; lower starting dose recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201839\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201789\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9703&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Nisoldipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Nisoldipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Nisoldipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Nisoldipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201811\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Peak concentrations of nisoldipine may be significantly increased if taken with high-lipid foods; however, total exposure (AUC) may be reduced. Grapefruit juice has been shown to significantly increase the bioavailability of nisoldipine. Management: Take on an empty stomach 1 hour before or 2 hours after a meal. Avoid a high-fat diet. Avoid grapefruit products before and after dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201790\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063538\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies when using doses that were not maternally toxic. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21123258\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nisoldipine is excreted into breast milk. The manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063542\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take on an empty stomach (1 hour before or 2 hours after a meal). Avoid grapefruit juice before and after dosing. Avoid grapefuit juice; avoid high-fat diet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063543\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50404243\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;60 years: Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;60 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with diabetes: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes and hypertension: </b>The American Diabetes Association (ADA) guidelines (ADA 2017a; ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years <b>and</b> at high risk of cardiovascular disease: Goal of therapy is SBP &lt;130 mm Hg and DBP &lt;80 mm Hg (if can be achieved without undue treatment burden).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (healthy <b>or </b>complex/intermediate health): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (very complex/poor health): Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201783\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a dihydropyridine calcium channel blocker, structurally similar to nifedipine, nisoldipine impedes the movement of calcium ions into vascular smooth muscle and cardiac muscle. Dihydropyridines are potent vasodilators and are not as likely to suppress cardiac contractility and slow cardiac conduction as other calcium antagonists such as verapamil and diltiazem; nisoldipine is 5-10 times as potent a vasodilator as nifedipine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201799\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &gt;24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed. Peak concentrations significantly increased with high-lipid meals; however, AUC is reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic; 1 active metabolite (10% of activity of parent); first-pass effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 9-18 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 4-14 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 80% as inactive metabolites); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201802\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Nisoldipine ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5 mg (100): $614.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17 mg (100): $769.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,645.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25.5 mg (100): $839.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,794.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">34 mg (100): $839.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,794.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Sular Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.5 mg (100): $2,605.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17 mg (100): $2,605.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">34 mg (100): $2,605.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201803\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Angiolat (UY);</li>\n      <li>Baymycard (BG, DE, HN, HU, JP);</li>\n      <li>Bo Ping (CN);</li>\n      <li>Corasol (CL);</li>\n      <li>Ke Di (CN);</li>\n      <li>Mo Tai (CN);</li>\n      <li>Nisodipen (AR);</li>\n      <li>Nisoldin (KR);</li>\n      <li>Sular (ES);</li>\n      <li>Syscor (AT, BE, CH, ES, FI, GR, IT, LU, NL, NZ, PL, TW);</li>\n      <li>Syscor CC (BB, BM, BS, BZ, GY, JM, NL, NZ, SR, TT);</li>\n      <li>Syscor MR (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979896\"></a>American Diabetes Association (ADA). 9. Cardiovascular disease and risk management. <i>Diabetes Care. </i>2017a;40(suppl 1):S75-S87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/27979896/pubmed\" target=\"_blank\" id=\"27979896\">27979896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979898\"></a>American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &quot;2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2011, 123(18):e426-579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/21444888/pubmed\" target=\"_blank\" id=\"21444888\">21444888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo; <i>J Am Coll Cardiol</i>, 2000, 36(3):970-1062.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/10987629/pubmed\" target=\"_blank\" id=\"10987629\">10987629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estacio RO, Jeffers BW, Hiatt WR, et al, &ldquo;The Effect of Nisoldipine as Compared With Enalapril on Cardiovascular Outcomes in Patients With Noninsulin-Dependent Diabetes and Hypertension,&rdquo; <i>N Engl J Med</i>, 1998, 338(10):645-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/9486993/pubmed\" target=\"_blank\" id=\"9486993\">9486993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sular (nisoldipine) [prescribing information]. Florham Park, NJ: Shionogi Inc.; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nisoldipine-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9703 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201814\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201845\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201818\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201819\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210470\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F201820\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201793\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201780\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201797\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201796\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201852\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201787\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201800\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201784\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F201839\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201789\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201811\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201790\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6063538\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21123258\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6063542\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6063543\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50404243\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201783\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201799\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201802\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201803\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9703|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nisoldipine-patient-drug-information\" class=\"drug drug_patient\">Nisoldipine: Patient drug information</a></li></ul></div></div>","javascript":null}